IL18 and metabolic dysfunction-associated steatotic liver disease: Atorvastatin notably inhibits the activation of the NOD-like receptor family pyrin domain-containing 3 (NLRP3) inflammasome pathway triggered by cholesterol crystals, subsequently reducing the expression of pro-inflammatory cytokines IL-1β and IL-18, which are implicated in NAFLD progression.